CELLPRO CEPRATE TUMOR DEPLETION PHASE III TRIAL
This article was originally published in The Gray Sheet
Executive Summary
CELLPRO CEPRATE TUMOR DEPLETION PHASE III TRIAL is expected to begin this month in patients with multiple melanoma, CEO Richard Murdoch told the New York Society of Security Analysts at an Oct. 25 meeting. The 125-patient, 15-center study is designed to look at the tumor purging effect of stem cells that have been processed through the device. The study is slated to begin as soon as FDA grants final approval for the trial; FDA conducted an initial review of the protocol and asked for modifications related to the study endpoints, which CellPro submitted in mid-October.
You may also be interested in...
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.
Turning That Frown Upside Down: Treating Depression With Facial Botox Injections
In this episode of the In Vivo podcast, Eric Finzi, CEO of Healis Therapeutics, discusses how his company is targeting major depression, post-traumatic stress disorder and other mental illnesses using facial botox injections.